 |
|
|
| |
Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV
|
| |
| |
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C - (04/07/14)
Reported by Jules Levin
EASL April 9-13, 2014, London, UK
K Gupta1, M Seifer1, I Serra1, H Rashidzadeh1, S Luo1, M La Colla1, X-R Pan-Zhou1, C Chapron1, B Hernandez-Santiago1, C Parsy2, F-R Alexandre2, B Mayes1, S Bhadresa1, A Moussa1, R Rush1
1 Idenix Pharmaceuticals, Inc., Cambridge, MA, USA; 2Idenix Medicinal Chemistry Research Laboratory, Montpellier, France.
|
| |
|
|
|
|
|
